Peixin Shen

Title: Peixin Shen: Innovator in Immunomodulatory Medicines

Introduction

Peixin Shen is a prominent inventor based in Xi'an, China. He has made significant contributions to the field of immunomodulatory medicines, particularly in the treatment of neuromyelitis optica and immune rejection after skin transplantation. His innovative work has the potential to enhance clinical applications and improve patient outcomes.

Latest Patents

Peixin Shen holds a patent for the "Applications of ellagic acid in preparation of immunomodulatory medicines for treatment of neuromyelitis optica or immune rejection after skin transplantation." This patent focuses on the use of ellagic acid and its metabolic derivative, urolithin, in developing immunomodulatory medicines. The research utilizes classical animal models of autoimmunity and immunoregulation, such as experimental autoimmune encephalomyelitis and neuromyelitis optica mouse models. The experiments demonstrate that ellagic acid and its derivatives significantly improve recovery from autoimmune conditions and inhibit inflammatory cell infiltration into the central nervous system.

Career Highlights

Peixin Shen is affiliated with Shaanxi Normal University, where he conducts his research and develops innovative solutions in immunology. His work has garnered attention for its clinical application value and potential for future development.

Collaborations

Peixin Shen collaborates with notable colleagues, including Yuan Zhang and Wenhui Qi, to advance research in immunomodulatory therapies. Their combined expertise enhances the quality and impact of their work.

Conclusion

Peixin Shen's contributions to the field of immunomodulatory medicines highlight the importance of innovation in medical research. His patent on ellagic acid showcases the potential for new treatments that can significantly improve patient care.